Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25642802 | 1.00 | KDM4E (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL18367814 | 1.00 | KDM4E (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL21165454 | 0.94 | KDM4E (0.32) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL1062380 | 0.91 | — | — | |
| SCHEMBL14414058 | 0.91 | USP2 (0.42) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL7705221 | 0.91 | USP2 (0.42) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL6587475 | 0.88 | KDM4E (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL6587467 | 0.88 | KDM4E (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL6587462 | 0.88 | KDM4E (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL121125 | 0.82 | LMNA (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472810-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-10-18 | — | — | US | disclosed |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2021-08-05 | — | — | US | disclosed |
| US-10858362-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-12-08 | — | — | US | disclosed |
| EP-3204387-B1 | TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2019-06-12 | — | — | EP | disclosed |
| EP-3288944-B1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2019-06-12 | — | — | EP | disclosed |
| US-10150771-B2 | Triazolopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2018-12-11 | — | — | US | disclosed |
| US-10144732-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-10011606-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2018-07-03 | — | — | US | disclosed |
| EP-3288944-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. Lundbeck A/S (DK) | 2018-03-07 | — | — | EP | disclosed |
| EP-3286194-A1 | IMIDAZOTRIAZINONES AS PDE1 INHIBITORS | H. Lundbeck A/S (DK) | 2018-02-28 | — | — | EP | disclosed |
| US-20160318939-A1 | Imidazopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | US | disclosed |
| WO-2016174188-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016170064-A1 | IMIDAZOTRIAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2016-10-27 | — | — | WO | disclosed |
| US-20160311831-A1 | Imidazotriazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2016-10-27 | — | — | US | disclosed |
| WO-2016055618-A1 | TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2016-04-14 | — | — | WO | disclosed |
| WO-2015188051-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015188051-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| US-6911468-B2 | Tyrosine phosphatase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | KDM4E 171/4885USP2 1150/4885ALDH1A1 2470/4885 |
| US-20160318939-A1 | Imidazopyrazinones as PDE1 Inhibitors | PDE12, PDE4A, PDE5A | KDM4E 1397/4885USP2 1844/4885ALDH1A1 110/4885 |
| US-10858362-B2 | Imidazopyrazinones as PDE1 inhibitors | PDE12, PDE4A, PDE5A | KDM4E 1397/4885USP2 1844/4885ALDH1A1 110/4885 |
| US-10150771-B2 | Triazolopyrazinones as PDE1 inhibitors | PDE5A, PDE4A, PDE12 | KDM4E 1523/4885USP2 1755/4885ALDH1A1 298/4885 |
| US-20160311831-A1 | Imidazotriazinones as PDE1 Inhibitors | PDE1A, PDE1B, PDE4A | KDM4E 2071/4885USP2 1800/4885ALDH1A1 125/4885 |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | PDE12, PDE4A, PDE5A | KDM4E 1397/4885USP2 1844/4885ALDH1A1 110/4885 |
| US-11472810-B2 | Imidazopyrazinones as PDE1 inhibitors | PDE12, PDE4A, PDE5A | KDM4E 1397/4885USP2 1844/4885ALDH1A1 110/4885 |
| US-10011606-B2 | Imidazopyrazinones as PDE1 inhibitors | PDE12, PDE4A, PDE5A | KDM4E 1397/4885USP2 1844/4885ALDH1A1 110/4885 |
| US-10144732-B2 | ATX modulating agents | ENPP2, ATXN10, ATXN2 | KDM4E 2571/4885USP2 1202/4885ALDH1A1 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.